Verastem, with Phase 3 Results, to Request FDA... - CLL Support

CLL Support

23,089 members39,652 posts

Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

wmay13241 profile image
0 Replies

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.

The oral therapy nearly halved the risk of disease progression or death, and held patients progression-free for a median of 13.3 months. This was 3.4 months longer than in patients treated with Arzerra.

Source: phx.corporate-ir.net/phoeni...

Written by
wmay13241 profile image
wmay13241
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018

FDA Approves Duvelisib for CLL and Follicular Lymphoma Published: Monday, Sep 24, 2018 The FDA has...

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce...

FDA Approves Venetoclax (VENCLEXTA) For CLL or SLL with or without 17p deletion, who have received at least one prior therapy

FDA Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic...

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Jan 19,...

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...